Loading...

Bright Minds Biosciences Inc.

DRUG.CNCNQ
Healthcare
Biotechnology
CA$58.56
CA$-1.46(-2.43%)

Bright Minds Biosciences Inc. (DRUG.CN) Company Profile & Overview

Explore Bright Minds Biosciences Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Bright Minds Biosciences Inc. (DRUG.CN) Company Profile & Overview

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

SectorHealthcare
IndustryBiotechnology
CEOIan McDonald

Contact Information

647 407 2515
1500 – 1055 West Georgia Street, New York City, BC, V6E 4N7

Company Facts

IPO DateFeb 9, 2021
CountryCA
Actively Trading

Frequently Asked Questions

;